T. V. Rakitina, A. A. Zeifman, F. N. Novikov, O. V. Stroganov, V. S. Stroylov, I. Svitanko, A. Frank-Kamenetskii, G. G. Chilov, “Novel PARP1 inhibitors potentiate doxorubicin antitumor activity in vitro”, Mendeleev Commun., 2015, Volume 25, Issue 5,Pages <nobr>364–366</nobr>

RUS ENG

JOURNALS // Mendeleev Communications // Archive

Mendeleev Commun., 2015 Volume 25, Issue 5, Pages 364–366 (Mi mendc2410)

This article is cited in 2 papers

Communications

Novel PARP1 inhibitors potentiate doxorubicin antitumor activity in vitro

T. V. Rakitina^ab, A. A. Zeifman^c, F. N. Novikov^c, O. V. Stroganov^c, V. S. Stroylov^c, I. Svitanko^cd, A. Frank-Kamenetskii^a, G. G. Chilov^c

^a National Research Centre 'Kurchatov Institute', Moscow, Russian Federation
^b M.M. Shemyakin–Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^c N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
^d Department of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russian Federation

Abstract: Six novel potential PARP1 inhibitors were identified by means of substructure search and molecular docking into PAPR1 active site; one compound (STK970217) potentiated the cytotoxicity of doxorubicin in hepatocellular carcinoma HepG2 cells being non-cytotoxic as a single agent, while three other identified compounds inhibited the growth of HepG2 cells both individually and in combination with doxorubicin.

Language: English

DOI: 10.1016/j.mencom.2015.09.016

© Steklov Math. Inst. of RAS, 2025